FNCH

Finch Announces Reverse Stock Split of Common Stock

Retrieved on: 
Friday, June 9, 2023
Transfer, Intellectual property, Shareholder, Bangladesh Securities and Exchange Commission, Finch, CUSIP, Security (finance), FNCH, AST, Book

The reverse stock split is intended to increase the per share trading price of Finch’s common stock to enable Finch to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.

Key Points: 
  • The reverse stock split is intended to increase the per share trading price of Finch’s common stock to enable Finch to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.
  • The reverse stock split affects all issued and outstanding shares of Finch’s common stock uniformly and will not alter any stockholder’s percentage interest in Finch’s equity, except to the extent that the reverse stock split results in some stockholders receiving cash in lieu of any fractional shares.
  • The par value of Finch’s common stock will remain unchanged at $0.001 per share after the reverse stock split.
  • There will be no change in the authorized number of shares of common stock or preferred stock after the reverse stock split.

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, May 10, 2023
Agreement, Intellectual property, IPR, CDI, University, Inflammatory Bowel Diseases, Biotechnology, Clinical trial, Pharmacokinetics, Research, Doctor of Philosophy, Microbiota, Șaeș, Public expenditure, Patent, Patient, CFO, UMN, Bacteria, Hospital, R, FNCH, Therapy, Psychotherapy discontinuation, Clostridioides difficile infection, Safety, Pharmaceutical industry, Brigham, Finch, Ulcerative colitis

SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates.

Key Points: 
  • SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates.
  • Finch reported a net loss of $63.9 million for the first quarter of 2023, compared to a net loss of $24.6 million for the same period in 2022.
  • Research and development expenses were $8.6 million for the first quarter of 2023, compared to $15.5 million for the same period in 2022.
  • General and administrative expenses were $9.6 million for the first quarter of 2023, compared to $9.4 million for the same period in 2022.

Finch Therapeutics Announces Executive Leadership Transitions

Retrieved on: 
Tuesday, April 25, 2023
Danforth, Teva Pharmaceuticals, Cleary Gottlieb Steen & Hamilton, Intellectual property, BS, University, Cleary, Washington College of Law, Case Western Reserve University, Research, Genentech, Doctor of Philosophy, PwC, MS, Eli Lilly, Bristol Myers Squibb, Bentley University, Johns Hopkins University, Patient, CPA, Invention, CFO, FNCH, Therapy, Chemical engineering, Management, Pharmaceutical industry, Biotechnology, Finch, Roivant Sciences

SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced the appointment of Matthew P. Blischak as Chief Executive Officer, effective May 16, 2023. In conjunction with the appointment of Mr. Blischak, Mark Smith, PhD, will conclude his role as Chief Executive Officer and as a member of the Company’s board of directors, effective May 15, 2023. Dr. Smith is expected to remain engaged with the Company as a scientific and strategic advisor. In addition, Finch announced the appointment of Lance Thibault as Chief Financial Officer, effective May 16, 2023. In conjunction with the appointment of Mr. Thibault, Marc Blaustein will conclude his role as Chief Operating Officer and as the Company’s principal financial officer, effective May 15, 2023. Mr. Blaustein is expected to remain engaged with the Company as a strategic advisor.

Key Points: 
  • In addition, Finch announced the appointment of Lance Thibault as Chief Financial Officer, effective May 16, 2023.
  • “It is my privilege to welcome Matt as our next Chief Executive Officer.
  • “I am thrilled with the opportunity to lead Finch through this next stage in the Company’s journey,” said Matthew Blischak, incoming Chief Executive Officer of Finch Therapeutics.
  • His leadership has been critical in positioning the Company for success in this next chapter of our journey.”

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement

Retrieved on: 
Tuesday, April 18, 2023
Intellectual property, University, Clinical trial, Pharmacokinetics, Doctor of Philosophy, Ulcerative colitis, Trial of the century, Microbiota, Patent, Patient, Hospital, Bacteria, FNCH, Therapy, Safety, Disease, Pharmaceutical industry, Brigham, Finch

The Company also announced updates to its license agreement with the University of Minnesota.

Key Points: 
  • The Company also announced updates to its license agreement with the University of Minnesota.
  • Under the clinical trial agreement, Brigham and Women’s Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101 in patients with mild-to-moderate ulcerative colitis.
  • “The clinical trial agreement to evaluate CP101 in ulcerative colitis builds on many years of work at Finch to develop product candidates to serve this important unmet medical need.
  • I am also pleased to extend our long-standing relationship with the University of Minnesota, which we believe positions us to continue to advance our microbiome technology through collaborations and partnerships.”

Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, March 23, 2023
Prejudice, Workforce, Patent, Intellectual property, CDI, University, University of Minnesota, IBD, Spectrum, Research, Doctor of Philosophy, Șaeș, Inflammatory bowel disease, Public expenditure, Clinical trial, ASD, UMN, R, FNCH, Therapy, Second Half, Clostridioides difficile infection, HBV, Pharmaceutical industry, Video game, G&A, Finch

SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter and full year 2022 financial results and provided business updates.

Key Points: 
  • SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter and full year 2022 financial results and provided business updates.
  • Finch reported a net loss of $27.0 million for the fourth quarter of 2022, compared to a net loss of $19.1 million for the same period in 2021.
  • R&D expenses were $16.6 million for the fourth quarter of 2022, compared to $14.8 million for the same period in 2021.
  • G&A expenses were $10.9 million for the fourth quarter of 2022, compared to $5.1 million for the same period in 2021.

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Retrieved on: 
Tuesday, January 24, 2023
Autism, CDI, Therapy, Clostridioides difficile infection, Patient, Ulcerative colitis, FNCH, Workforce, Research, Doctor of Philosophy, Pharmaceutical industry, Finch

SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.

Key Points: 
  • SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets.
  • As a result of this decision, Finch is reducing its workforce by approximately 95%.
  • Finch has a portfolio of microbiome assets including CP101, an investigational orally administered microbiome candidate with positive data from a Phase 2 placebo-controlled trial and a Phase 2 open-label trial in recurrent CDI.
  • Additionally, Finch has pre-clinical microbiome assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder.

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, American College of Gastroenterology, CDI, Ulcerative colitis, ACG, Marketing, Leadership, Doctor of Philosophy, Patent, U.S. Securities and Exchange Commission, FDA, HBV, Interim, Autism, Food, American College, GI, Hepatitis B, Breakthrough therapy, Inflammatory bowel disease, Takeda, FNCH, G&A, COVID-19, BLA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, ASD, R, IBD, SEC, Failure, Annual report, Clostridioides difficile infection, Safety, Company, Program, Research, Sequah Medicine Company, MBA, Patient, Crohn's disease, Security (finance), PRISM, Salix Pharmaceuticals, Recurrence, MD, SOC, Pharmaceutical industry, Finch, Willow

SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022.
  • Presented CP101 PRISM-EXT Biomarker Data at ACG 2022: In October 2022, Finch announced the presentation of biomarker data from the PRISM-EXT open-label trial of CP101 in recurrent CDI at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
  • Finch reported a net loss of $40.4 million for the third quarter of 2022, compared to a net loss of $10.0 million for the same period in 2021.
  • Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Ulcerative colitis, Doctor of Philosophy, Food, Autism, Breakthrough therapy, FNCH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, MBA, Crohn's disease, News, MD, Pharmaceutical industry, Management, Finch

Replays of the webcasts will be available on Finchs website for approximately 30 days after each event.

Key Points: 
  • Replays of the webcasts will be available on Finchs website for approximately 30 days after each event.
  • Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
  • Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com .
  • Human-First Discovery is a registered trademark of Finch Therapeutics Group, Inc.

Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Autism, Therapy, Risk, FNCH, SEC, Hospital, American College of Gastroenterology, SOC, Hope, Diversity, PRISM, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diarrhea, CDI, Patient, Annual report, Abdominal pain, MBA, Crohn's disease, Clostridioides difficile infection, MPH, Security (finance), Harvard Medical School, Food, Publication, Marketing, ACG, Pharmacokinetics, Â, Patent, Safety, Recurrence, Cone Health Women's Hospital, GLOBE, Ulcerative colitis, MA, Failure, Death, American College, FDA, COVID-19, Subclinical infection, Pharmaceutical industry, Vaccine, Brigham, MD, Finch

Finch also announced today that the company has proceeded with patient dosing in PRISM4, a Phase 3 trial of CP101 for the prevention of recurrent CDI.

Key Points: 
  • Finch also announced today that the company has proceeded with patient dosing in PRISM4, a Phase 3 trial of CP101 for the prevention of recurrent CDI.
  • These results further our understanding of the pharmacokinetics and pharmacodynamics of CP101 and support our efforts to optimize engraftment of CP101 microbes.
  • Higher engraftment of CP101-associated taxa and improvement in diversity were both associated with prevention of CDI recurrence through week 8.
  • PRISM-EXT was a Phase 2, multi-center, open-label trial of CP101 for the prevention of recurrent CDI in adults with one or more CDI recurrences.

Finch Therapeutics Provides Business Update

Retrieved on: 
Thursday, September 1, 2022
Security (finance), COVID-19, Workforce, Inflammatory bowel disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Doctor of Philosophy, FNCH, Food, Line 6 Finch West, SEC, IBD, Review, U.S. Securities and Exchange Commission, Patent, GLOBE, Breakthrough therapy, Company, Failure, Clostridioides difficile infection, Annual report, Ulcerative colitis, Autism, Marketing, Patient, Pharmaceutical industry, Takeda, Finch

SOMERVILLE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio.

Key Points: 
  • SOMERVILLE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio.
  • Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
  • With the capabilities to develop both complete and targeted microbiome therapeutics, Finch has a rich pipeline of candidates designed to address a wide range of unmet medical needs.
  • Except to the extent required by law, Finch undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.